The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Svechnikova E.V.

Novosibirsk State Medical University

Marshani Z.B.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation

Fomin K.A.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation;
Vladimirsky Moscow Regional Research Clinical Institute

Evdokimov E.Yu.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation;
Central Research Institute of Epidemiology

New coronavirus infection in the aspect of psoriasis

Authors:

Svechnikova E.V., Marshani Z.B., Fomin K.A., Evdokimov E.Yu.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2021;20(3): 77‑84

DOI: 10.17116/klinderma20212003177

Views: 1824

Downloaded: 54

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Svechnikova EV, Marshani ZB, Fomin KA, Evdokimov EYu. New coronavirus infection in the aspect of psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2021;20(3):77‑84. (In Russ.)
https://doi.org/10.17116/klinderma20212003177

 
МСФ на ЯМ
Close metadata
Recommended articles:
The role of tele­medicine in dermatology with examples on the orga­nization of services for patients with psoriasis and acne. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(2):111-117
Age features of immu­nity to SARS-CoV-2 of metropolis popu­lation in the dyna­mics. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(2):118-128
A clinical case of the new-onset bipo­lar affe­ctive diso­rder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129
Causes of hospital mortality in adults based on medi­cal certificates of death. Russian Journal of Preventive Medi­cine. 2024;(3):7-13
Anti­biotic resi­stance of the upper respiratory tract microbiota in children with the new coro­navirus infe­ction in Ryazan. Russian Journal of Preventive Medi­cine. 2024;(3):45-51
Comparison of the clinical performance of immu­nochromatographic tests for the dete­ction of SARS-CoV-2 anti­gens with data from inde­pendent studies. Labo­ratory Service. 2024;(1):13-19
Adve­rse peri­natal outcomes in COVID-19. Analysis of a series of clinical obse­rvations. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):86-90
Staging of COVID-19 morphological mani­festations in lungs depe­nding on disease dura­tion. Fore­nsic Medi­cal Expe­rtise. 2024;(2):28-31
Russian COVID-19 vaccines as a risk factor of myopericarditis in patients with or without previous infe­ction. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):184-193
Exosomes’ role in inte­rcellular inte­ractions in different variants of lung injury in fatal cases of COVID-19. Russian Journal of Archive of Pathology. 2024;(2):22-29

In a relatively short period of its existence, the new coronavirus has had a huge impact on the health care system and social infrastructure around the world. Despite the fact that majority of those infected have an asymptomatic or mild course of the disease, in a number of patients the infection becomes threatening and can lead to death. Among the risk factors for an unfavorable outcome, senior age, the presence of comorbidities and, presumably, immunosuppression were identified. This situation also affect the dermatological practice where a number of patients need long-term immunosuppressive therapy. Patients with psoriasis receiving genetically engineered biological drugs (GEBDs) make up a significant proportion of this cohort and discontinuation of treatment can lead to negative consequences. The accumulated knowledge suggests that usage of certain GEBD does not increase the risks of COVID-19 but also can beneficially affect the underlying cytokine storm. Thus, during a pandemic the dermatologists all over the world were faced with the question of the possibility and feasibility of continuing the use of GEBD in patients with psoriasis. The characteristics of the coronavirus, the pathogenesis, clinical manifestations and diagnostics of COVID-19 are presented, and data on the possibility of continuing genetically engineered therapy in patients with psoriasis are considered. In addition, the article presents own observations of the new coronavirus infection in patients with psoriasis based on GEBD.

Keywords:

SARS-CoV-2
COVID-19
psoriasis
genetically engineered biological drugs
IL-17 inhibitor

Authors:

Svechnikova E.V.

Novosibirsk State Medical University

Marshani Z.B.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation

Fomin K.A.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation;
Vladimirsky Moscow Regional Research Clinical Institute

Evdokimov E.Yu.

Polyclinic No. 1 of Administrative Directorate of the President of the Russian Federation;
Central Research Institute of Epidemiology

Received:

03.03.2021

Accepted:

16.04.2021

List of references:

  1. Li X, Wang W, Zhao X. Transmission dynamics and evolutionary history of 2019-nCoV. J Med Virol. 2020;92(5):501-511.  https://doi.org/10.1002/jmv.25701
  2. Vsemirnaya organizatsiya zdravookhraneniya, elektronnyj resurs. (In Russ.) https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  3. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China — key questions for impact assessment. N Engl J Med. 2020;382(8):692-694.  https://doi.org/10.1056/NEJMp2000929
  4. Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536-544.  https://doi.org/10.1038/s41564-020-0695-z
  5. Lin K, Fong DYT, Zhu B, Karlberg J. Environmental factors on the SARS epidemic: air temperature, passage of time and multiplicative effect of hospital infection. Epidemiology & Infection. 2006;134(2):223-230.  https://doi.org/10.1017/S0950268805005054
  6. Sironi M, Hasnain SE, Rosenthal B, et al. SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective [published online ahead of print, 2020 May 29]. Infect Genet Evol. 2020;84:104384. https://doi.org/10.1016/j.meegid.2020.104384
  7. Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective. J Med Virol. 2020; 92(6):639-644.  https://doi.org/10.1002/jmv.25749
  8. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860-868.  https://doi.org/10.1126/science.abb5793
  9. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis. 2020;94:44-48.  https://doi.org/10.1016/j.ijid.2020.03.004
  10. Rastogi YR, Sharma A, Nagraik R, Aygün A, Şen F. The novel coronavirus 2019-nCoV: Its evolution and transmission into humans causing global COVID-19 pandemic [published online ahead of print, May 26, 2020]. Int J Environ Sci Technol (Tehran). 2020;1-8.  https://doi.org/10.1007/s13762-020-02781-2
  11. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak — an update on the status. Mil Med Res. 2020;7(1):11. Published Mar 13, 2020. https://doi.org/10.1186/s40779-020-00240-0
  12. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574.  https://doi.org/10.1016/S0140-6736(20)30251-8
  13. Chan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013;21(10):544-555.  https://doi.org/10.1016/j.tim.2013.05.005
  14. Luk HKH, Li X, Fung J, Lau SKP, Woo PCY. Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol. 2019;71: 21-30.  https://doi.org/10.1016/j.meegid.2019.03.001
  15. Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 2018;16(8):e3000003. Published Aug 13, 2018. https://doi.org/10.1371/journal.pbio.3000003
  16. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-423.  https://doi.org/10.1002/jmv.25681
  17. Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan [published correction appears in Emerg Microbes Infect. 2020;9(1):540]. Emerg Microbes Infect. 2020;9(1):221-236. Published Jan 28, 2020. https://doi.org/10.1080/22221751.2020.1719902
  18. Uddin M, Mustafa F, Rizvi TA, et al. SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. Viruses. 2020;12(5):526. Published May 10, 2020. https://doi.org/10.3390/v12050526
  19. Su S, Wong G, Shi W, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016;24(6):490-502.  https://doi.org/10.1016/j.tim.2016.03.003
  20. Yeung ML, Yao Y, Jia L, et al. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nat Microbiol. 2016;1(3): 16004. Published Feb 22, 2016. https://doi.org/10.1038/nmicrobiol.2016.4
  21. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-1325. https://doi.org/10.1016/s0140-6736(03)13077-2
  22. Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther. 2020; 5(1):84. Published May 29, 2020. https://doi.org/10.1038/s41392-020-0191-1
  23. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50(SI-1):620-632. Published Apr 21, 2020. https://doi.org/10.3906/sag-2004-168
  24. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8.  https://doi.org/10.1016/j.cell.2020.02.052
  25. Luan J, Lu Y, Jin X, Zhang L. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020;526(1):165-169.  https://doi.org/10.1016/j.bbrc.2020.03.047
  26. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-590.  https://doi.org/10.1007/s00134-020-05985-9
  27. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203(2):631-637.  https://doi.org/10.1002/path.1570
  28. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681-687.  https://doi.org/10.1038/s41591-020-0868-6
  29. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020; 9(1):45. Published Apr 28, 2020. https://doi.org/10.1186/s40249-020-00662-x
  30. Amiral J, Vissac AM, Seghatchian J. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients? Transfus Apher Sci. 2020;59(3):102804. https://doi.org/10.1016/j.transci.2020.102804
  31. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10):1456-1474. https://doi.org/10.1161/CIRCRESAHA.120.317015
  32. Wang H, Yang P, Liu K, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008;18(2):290-301.  https://doi.org/10.1038/cr.2008.15
  33. Park WB, Kwon NJ, Choi SJ, et al. Virus Isolation from the First Patient with SARS-CoV-2 in Korea. J Korean Med Sci. 2020;35(7):e84. Published Feb 24, 2020. https://doi.org/10.3346/jkms.2020.35.e84
  34. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6): 363-374.  https://doi.org/10.1038/s41577-020-0311-8
  35. Braciale TJ, Hahn YS. Immunity to viruses. Immunol Rev. 2013;255(1):5-12.  https://doi.org/10.1111/imr.12109
  36. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-432.  https://doi.org/10.1002/jmv.25685
  37. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-384.  https://doi.org/10.1038/ni.1863
  38. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. Jan 30, 2020]. Lancet. 2020;395(10223):497-506.  https://doi.org/10.1016/S0140-6736(20)30183-5
  39. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. Feb 25, 2020]. Lancet Respir Med. 2020;8(4):420-422.  https://doi.org/10.1016/S2213-2600(20)30076-X
  40. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020;15(5):700-704.  https://doi.org/10.1016/j.jtho.2020.02.010
  41. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108.  https://doi.org/10.1016/j.jpha.2020.03.001
  42. Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16(10):1718-1723. Published Mar 15, 2020. https://doi.org/10.7150/ijbs.45123
  43. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 [published online ahead of print, Mar 28, 2020]. Clin Infect Dis. 2020;ciaa344. https://doi.org/10.1093/cid/ciaa344
  44. Jenkins MM, McCaw TR, Goepfert PA. Mechanistic inferences from clinical reports of SARS-CoV-2. Infect Dis (Lond). 2020;52(8):527-537.  https://doi.org/10.1080/23744235.2020.1769853
  45. Thiel V, Weber F. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev. 2008;19(2):121-132.  https://doi.org/10.1016/j.cytogfr.2008.01.001
  46. Kindler E, Thiel V. SARS-CoV and IFN: Too Little, Too Late. Cell Host Microbe. 2016;19(2):139-141.  https://doi.org/10.1016/j.chom.2016.01.012
  47. Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42.  https://doi.org/10.1016/j.cytogfr.2020.04.002
  48. Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3): 282-289.  https://doi.org/10.1002/path.1440
  49. Zhao J, Zhao J, Legge K, Perlman S. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. J Clin Invest. 2011;121(12): 4921-4930. https://doi.org/10.1172/JCI59777
  50. Kam KQ, Yung CF, Cui L, et al. A Well Infant With Coronavirus Disease 2019 With High Viral Load. Clin Infect Dis. 2020;71(15):847-849.  https://doi.org/10.1093/cid/ciaa201
  51. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore [published online ahead of print, Mar 03, 2020] [published correction appears in  https://doi.org/10.1001/jama.2020.3204
  52. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019‐nCoV. Biochem Biophys Res Commun. 2020;525(1):135-140.  https://doi.org/10.1016/j.bbrc.2020.02.071
  53. Khalili M, Karamouzian M, Nasiri N, Javadi S, Mirzazadeh A, Sharifi H. Epidemiological characteristics of COVID-19: A systematic review and meta-analysis. Epidemiology and Infection. 2020;148:E130. https://doi.org/10.1017/S0950268820001430
  54. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382(12):1177-1179. https://doi.org/10.1056/NEJMc2001737
  55. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151.  https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003
  56. Torres T, Puig L. Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. Am J Clin Dermatol. 2020;21(3):307-311.  https://doi.org/10.1007/s40257-020-00514-2
  57. Dugail I, Amri EZ, Vitale N. High prevalence for obesity in severe COVID-19: Possible links and perspectives towards patient stratification [published online ahead of print, July 08, 2020]. Biochimie. 2020;S0300-9084(20)30155-3.  https://doi.org/10.1016/j.biochi.2020.07.001
  58. Massey PR, Jones KM. Going viral: A brief history of Chilblain-like skin lesions (“COVID toes”) amidst the COVID-19 pandemic [published online ahead of print, May 23, 2020]. Semin Oncol. 2020;S0093-7754(20)30051-8.  https://doi.org/10.1053/j.seminoncol.2020.05.012
  59. Catalá Gonzalo A, Galván Casas C. COVID-19 and the Skin [published online ahead of print, July 16, 2020]. Actas Dermosifiliogr. 2020;111(6):447-449.  https://doi.org/10.1016/j.adengl.2020.04.014
  60. Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue [published online ahead of print, June 01, 2020]. Br J Dermatol. 2020; 183(3):431-442.  https://doi.org/10.1111/bjd.19264
  61. Matar S, Oulès B, Sohier P, et al. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature [published online ahead of print, June 26, 2020]. J Eur Acad Dermatol Venereol. 2020;34(11):686-689.  https://doi.org/10.1111/jdv.16775
  62. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77.  https://doi.org/10.1111/bjd.19163
  63. Wollina U. Challenges of COVID-19 pandemic for dermatology [published online ahead of print, Apr 20, 2020]. Dermatol Ther. 2020;e13430. https://doi.org/10.1111/dth.13430
  64. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020;20(4):411-412.  https://doi.org/10.1016/S1473-3099(20)30113-4
  65. Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020;16(3):240-246.  https://doi.org/10.1007/s12519-020-00345-5
  66. Zhang Y, Cao W, Xiao M, et al. Zhonghua Xue Ye Xue Za Zhi. 2020;41(0):E006. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0006
  67. Amerio P, Prignano F, Giuliani F, Gualdi G. COVID-19 and psoriasis: Should we fear for patients treated with biologics? [published online ahead of print, Apr 20, 2020]. Dermatol Ther. 2020;e13434. https://doi.org/10.1111/dth.13434
  68. Stein RA. COVID-19 and rationally layered social distancing. Int J Clin Pract. 2020;74(7):e13501. https://doi.org/10.1111/ijcp.13501
  69. Zhou L, Liu K, Liu HG. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(4): 281-284.  https://doi.org/10.3760/cma.j.cn112147-20200229-00219
  70. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China [published correction appears in Nature. 2020; 580(7803):E7]. Nature. 2020;579(7798):265-269.  https://doi.org/10.1038/s41586-020-2008-3
  71. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15):762-768.  https://doi.org/10.1093/cid/ciaa248
  72. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229): 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
  73. Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2 [published online ahead of print, June 10, 2020]. Clin Chim Acta. 2020;509: 280-287.  https://doi.org/10.1016/j.cca.2020.06.017
  74. Lippi G, Mattiuzzi C, Bovo C, Plebani M. Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). Acta Biomed. 2020;91(2):137-145. Published May 11, 2020. https://doi.org/10.23750/abm.v91i2.9548
  75. Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. Front Pharmacol. 2020;11:117. Published Feb 25, 2020. https://doi.org/10.3389/fphar.2020.00117
  76. Kearns DG, Uppal S, Chat VS, Wu JJ. Use of systemic therapies for psoriasis in the COVID-19 era [published online ahead of print, May 27, 2020]. J Dermatolog Treat. 2020;1-14.  https://doi.org/10.1080/09546634.2020.1775774
  77. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201(6): 1605-1613. https://doi.org/10.4049/jimmunol.1800013
  78. Cohen JM, Perez-Chada LM, De Kouchkovsky D, Gehlhausen JR. Psoriasis and COVID-19: a multifactorial consideration. Journal of Dermatological Treatment. 2020;1.  https://doi.org/10.1080/09546634.2020.1782818
  79. Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhahfar S. Psoriasis and risk of the COVID-19 infection: Is there a role for Angiotensin Converting Enzyme (ACE)? Journal of Dermatological Treatment. 2020; 1-2:1-7.  https://doi.org/10.1080/09546634.2020.1782819
  80. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377-390.  https://doi.org/10.1016/j.jaad.2016.07.064

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.